Consistent with the findings of previous studies, our results showed that CD8+/CD4+ T cell ratio increased continuously post-infusion (Fig. 4A), and higher relative CD8+/CD4+ T cell ratio contributed to survival benefit in patients with gynecologic cancer (Fig. 4B, C and D). The gene discussed is CD8A; the disease is female reproductive organ cancer.